三抗原与单抗原乙型肝炎疫苗在成人中的免疫原性和安全性(PROTECT):随机双盲3期试验
这项多中心双盲3期试验将1607名成人随机分配接种三抗原乙肝疫苗(TAV)或单抗原疫苗(MAV)。
要点
- TAV在≥18岁成人中血清保护率非劣效于MAV,在≥45岁人群中优效。
- TAV组注射部位疼痛、压痛和肌痛发生率高于MAV,但总体安全性与MAV相似。
- 研究纳入病情控制稳定的常见慢性病成人,支持TAV用于预防HBV感染。
核心结论
- TAV在成人中安全性良好,可有效预防HBV感染,包括病情稳定控制的慢性病患者。
研究设计与样本
- 多中心、双盲、3期随机对照试验(PROTECT),在美国、芬兰、加拿大和比利时28个社区和医院站点开展。
- 共1607名≥18岁HBV血清阴性成人随机1:1接种TAV(10 μg)或MAV(20 μg),按研究中心和年龄分层,第0、28、168天肌肉注射1 mL,末次接种后随访24周。
关键数值与推荐
- 血清保护率定义为抗-HBs滴度≥10 mIU/mL的参与者百分比。
- 非劣效界值:组间差异95%CI下限大于-5%。
- 非劣效性在≥18岁符合方案集中评估,优效性在≥45岁接受至少一剂且至少有一个可评估免疫原性样本的全分析集中评估。
临床怎么用
- 对于≥18岁成人,尤其是≥45岁人群,TAV可提供比MAV更高的血清保护率。
- 接种TAV时需告知局部疼痛、压痛和肌痛发生率较高,但多为轻中度。
- 病情控制稳定的常见慢性病成人可考虑接种TAV以预防HBV感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The seroprotection rate (SPR) of hepatitis B vaccination in adults is suboptimal. The aim of this study was to compare the SPR of a tri-antigenic hepatitis B vaccine (TAV), with a mono-antigenic vaccine (MAV) in adults of all ages. METHODS: This was a multicentre, double-blind, phase 3, randomised controlled trial (PROTECT) comparing the immunogenicity and safety of TAV with MAV in 28 community and hospital sites in the USA, Finland, Canada, and Belgium. Adults (aged ≥18 years) seronegative for hepatitis B virus (HBV), including those with well-controlled common chronic conditions, were randomly assigned (1:1) and stratified by study centre and age according to a web-based permuted blocked randomisation. Participants received either TAV or MAV which were administered as an intramuscular dose (1 mL) of TAV (10 μg; Sci-B-Vac, VBI Vaccines [SciVac, Rehovot, Israel]) or MAV (20 μg; Engerix-B [GlaxoSmithKline Biologicals, Rixensart, Belgium]) on days 0, 28, and 168 with six study visits and 24 weeks of follow-up after the third vaccination. Participants, investigators, and those assessing outcomes were masked to group assignment. The co-primary outcomes were to show non-inferiority of the SPRs 4 weeks after the third vaccination with TAV versus MAV in adults aged 18 years and older, as well as superiority in adults aged 45 years and older. SPR was defined as the percentage of participants attaining anti-HBs titres of 10 mIU/mL or higher. Non-inferiority of TAV to MAV was concluded if the lower limit of the 95% CI for the between-group difference was greater than -5%. Non-inferiority was assessed in the per-protocol set of participants (aged ≥18 years) and superiority was assessed in all participants (aged ≥45 years) who received at least one vaccination and had at least one evaluable immunogenicity sample after baseline (full analysis set). Safety analyses were a secondary outcome and included all participants who received at least one injection. This trial is registered at Clinicaltrials.gov (NCT03393754) and EudraCT (2017-001819-36) and is closed to new participants. FINDINGS: Between Dec 13, 2017, and April 8, 2019, 1607 participants (796 allocated to TAV and 811 allocated to MAV) were randomly assigned and distributed across age cohorts of 18-44 years (299 of 1607; 18·6%), 45-64 years (716 of 1607; 44·6%), and 65 years and older (592 of 1607; 36·8%). In participants aged 18 years and older, SPR was 91·4% (656 of 718) in the TAV group versus 76·5% (553 of 723) in the MAV group (difference 14·9%, 95% CI 11·2-18·6), showing non-inferiority in the per-protocol set. In participants aged 45 years and older, SPR was 89·4% (559 of 625) in the TAV group versus 73·1% (458 of 627) in the MAV group (difference 16·4%, 95% CI 12·2-20·7), showing superiority in the full analysis set. TAV was associated with higher rates of mild or moderate injection site pain (63·2% [503 of 796] in TAV vs 36·3% [294 of 811] in MAV), tenderness (60·8% [484 of 796] in TAV vs 34·8% [282 of 811] in MAV), and myalgia (34·7% [276 of 796] vs 24·3% [197 of 811] in MAV). Otherwise, the safety profile of TAV was similar to that of MAV. INTERPRETATION: The safety and efficacy of TAV shows its usefulness for the prevention of HBV infection in adults, including those with stable and controlled chronic conditions. FUNDING: VBI Vaccines.
引用
- Vesikari T, Langley JM, Segall N, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2021. PMID: 33989539. doi:10.1016/S1473-3099(20)30780-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。